|
 |
Nazwa handlowa |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Accofil |
Belgia, Chorwacja, Niemcy, Wielka Brytania |
|
Duperan |
Chile |
|
Filgen |
Argentyna, Chile |
|
Foltran |
Chile |
|
Granulokine |
Brazylia, Grecja, Włochy |
|
Hebervital |
KolumbiaKolumbia |
|
Inmunef |
KolumbiaKolumbia, Meksyk |
|
Leucosos |
KolumbiaKolumbia |
|
Lioplim |
Chile |
|
Neupogen |
Arabia Saudyjska, Australia, Austria, Belgia, Chile, Dania, Egipt, Ekwador, Finlandia, Francja , Hiszpania, Holandia, Iran, Irlandia, Kanada, KolumbiaKolumbia, Luksemburg, Malezja, Maroko, Meksyk, Niemcy, Norwegia, nowa Zelandia, Polska, Portugalia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Słowenia, Turcja, Wenezuela, Wielka Brytania, Zjednoczone Emiraty Arabskie |
|
Neutromax |
Argentyna |
|
Neutropine |
Argentyna |
|
Nivestim |
Belgia, Francja , Holandia, Niemcy, Norwegia, Wielka Brytania |
|
Ratiograstim |
Austria, Niemcy, Szwecja, Wielka Brytania |
|
Tevagrastim |
Belgia, Brazylia, Chile, Chorwacja, Hiszpania, Holandia, Niemcy, Norwegia, Szwajcaria, Szwecja, Wielka Brytania |
|
|
 |
 |
Bibliografia : Filgrastim |
|
|
typ |
publikacja |
| 99 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Czasopismo |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Czasopismo |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Czasopismo |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Czasopismo |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
Laboratorium |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3249 |
Czasopismo |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Czasopismo |
Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
Laboratorium |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3618 |
Laboratorium |
Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014 |
| 3828 |
plakat |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
plakat |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Czasopismo |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
Laboratorium |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4471 |
Laboratorium |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4521 |
Czasopismo |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
Laboratorium |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
|
|
